Oxford Biomedica PLC Director Dealings (3588A)
March 23 2017 - 9:47AM
UK Regulatory
TIDMOXB
RNS Number : 3588A
Oxford Biomedica PLC
23 March 2017
Director Dealings / Market Share Purchase
Oxford, UK - 23 March 2017: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the
Group, on Thursday 23 March 2017, acquired ordinary shares in the
Group as set out below, under the market share purchase agreement
outlined in the Group's announcement on 15 December 2015.
Under the market share purchase agreement, one-third of Dr
Tallarigo's fees as Chairman, after tax, are to be used to purchase
shares in Oxford BioMedica PLC on a monthly basis at the prevailing
market price.
Interest after
purchase
----------- --------- ---------- ---------------- ----------------------------
Director Title Price Number of Number % of total
/ PDMR per share Ordinary Shares of Ordinary issued
(p) acquired Shares share capital
----------- --------- ---------- ---------------- ------------ --------------
Dr Lorenzo
Tallarigo Chairman 5.3p 49,468 1,833,590 0.06%
----------- --------- ---------- ---------------- ------------ --------------
The issued share capital of the Group is 3,088,217,926 ordinary
1p shares.
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Tim Watts, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Chris Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and ex
vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
250 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHDMGZFFFDGNZM
(END) Dow Jones Newswires
March 23, 2017 09:47 ET (13:47 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Sep 2023 to Sep 2024